{"brief_title": "Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder", "brief_summary": "Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D17] less than or equal to 7) versus those subjects receiving placebo.", "condition": "Major Depressive Disorder", "intervention_type": "Drug", "intervention_name": "DVS-233 SR", "criteria": "Inclusion Criteria: - Outpatients - Sexually active women participating in the study must use a medically acceptable form of contraception - Subjects must have a primary diagnosis of major depressive disorder of 4 on Clinical Global Impressions-Severity scale (CGI-S) Exclusion Criteria: - Treatment with DVS-233 SR at any time in the past - Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1 - Known hypersensitivity to venlafaxine (IR or ER)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00073762.xml"}